Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

被引：0
|
作者：
Benjamin Tan
Adnan Khattak
Enriqueta Felip
Karen Kelly
Patricia Rich
Ding Wang
Christoph Helwig
Isabelle Dussault
Laureen S. Ojalvo
Nicolas Isambert
机构：
[1] Washington University School of Medicine,Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
[2] Fiona Stanley Hospital,undefined
[3] IOB-Quiron,undefined
[4] UVic-UCC,undefined
[5] University of California Davis Comprehensive Cancer Center,undefined
[6] Cancer Treatment Centers of America,undefined
[7] Piedmont Healthcare,undefined
[8] Henry Ford Cancer Institute,undefined
[9] Merck KGaA,undefined
[10] EMD Serono Research & Development Institute,undefined
[11] Inc.,undefined
[12] An affiliate of Merck KGaA,undefined
[13] Poitiers University Hospital,undefined
来源：
Targeted Oncology | 2021年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：435 / 446
页数：11
相关论文
共 50 条
  • [21] Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer
    Rajan, Arun
    Sater, Houssein Abdul
    Rahma, Osama
    Agajanian, Richy
    Lassoued, Wiem
    Marte, Jennifer L.
    Tsai, Yo-Ting
    Donahue, Renee N.
    Lamping, Elizabeth
    Bailey, Shania
    Weisman, Andrew
    Walter-Rodriguez, Beatriz
    Ito, Rena
    Vugmeyster, Yulia
    Sato, Masashi
    Machl, Andreas
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
  • [22] Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
    Barlesi, Fabrice
    Isambert, Nicolas
    Felip, Enriqueta
    Cho, Byoung Chul
    Lee, Dae Ho
    Peguero, Julio
    Jerusalem, Guy
    Penel, Nicolas
    Saada-Bouzid, Esma
    Garrido, Pilar
    Helwig, Christoph
    Locke, George
    Ojalvo, Laureen S.
    Gulley, James L.
    ONCOLOGIST, 2022, : 258 - 267
  • [23] PHASE 1B TRIAL OF FIRST-LINE BINTRAFUSP ALFA, A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF-β AND PD-L1, PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN CERVICAL CANCER
    Oaknin, A.
    Gil-Martin, M.
    Diver, E.
    Jehl, G.
    Gleicher, S. A.
    Chaudhary, S.
    Ojalvo, L.
    Hasegawa, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A51 - A52
  • [24] Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials
    Gulley, J.
    Lacouture, M. E.
    Spira, A.
    Verdaguer Mata, H.
    Yoo, C.
    Cho, B. C.
    Helwig, C.
    Halady, T.
    Valencia, C.
    Bajars, M.
    Strauss, J.
    Brownell, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S1181 - S1182
  • [25] M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with post-platinum esophageal adenocarcinoma (EAC): Preliminary results from a phase I cohort
    Tan, B.
    Khattak, A.
    Felip, E.
    Kelly, K.
    Rich, P.
    Wang, D.
    Helwig, C.
    Dussault, I.
    Ojalvo, L.
    Isambert, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 216 - 216
  • [26] Long-term follow-up of patients (pts) with human papillomavirus (HPV)eassociated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
    Strauss, J.
    Gatti-Mays, M.
    Cho, B. C.
    Hill, A.
    Salas, S.
    McClay, E.
    Redman, J.
    Sater, H. A.
    Lamping, E.
    Marte, J. L.
    Cordes, L.
    Bilusic, M.
    Karzai, F.
    Madan, R.
    Schlom, J.
    Jehl, G.
    Ojalvo, L. S.
    Gulley, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S829 - S829
  • [27] Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).
    Cho, Byoung Chul
    Daste, Amaury
    Ravaud, Alain
    Salas, Sebastien
    Isambert, Nicolas
    McClay, Edward Francis
    Awada, Ahmad
    Borel, Christian
    Helwig, Christoph
    Rolfe, P. Alexander
    Ojalvo, Laureen S.
    Gulley, James L.
    Penel, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.
    Liu, Dan
    Gong, Jifang
    Liu, Tianshu
    Li, KunYan
    Yin, Xianli
    Liu, Yunpeng
    Wang, Yongsheng
    Wang, Linna
    Wang, Wenliang
    Zhang, Yanyan
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort
    Cho, B. C.
    Daste, A.
    Ravaud, A.
    Salas, S.
    Isambert, N.
    McClay, E.
    Awada, A.
    Borel, C.
    Gulley, J.
    Ojalvo, L.
    Helwig, C.
    Rolfe, P. A.
    Penel, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-ß, in patients with advanced tumors
    Guo, Ye
    Liu, Baogang
    Lv, Dongqing
    Cheng, Ying
    Zhou, Tong
    Zhong, Yahua
    Hu, Changlu
    Chen, Gang
    Wu, Xiaohua
    Yin, Yongmei
    Wu, Lihua
    Chen, Zhendong
    Luo, Hong
    Zhou, Xiaohong
    Qin, Yanru
    Yang, Yuxing
    Luo, Suxia
    Ma, Yanjie
    Li, Yalin
    Hu, Guoqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345